Results from the SEE CLEAR II study

Results from the SEE CLEAR II study demonstrating the noninferiority of day-before P/MC dosing compared with
day-before 2 L of polyethylene glycol solution (2L PEG-3350) dosing were recently published.11 This report
summarizes the results from the SEE CLEAR I study, a phase 3, randomized, multicenter, assessor-blinded, noninferiority,
head-to-head study that evaluated the efficacy, safety, and tolerability of a split-dose administration of
P/MC versus a previously approved day-before dosing regimen of 2L PEG-3350 and two 5-mg bisacodyl tablets (Half-
Lytely and Bisacodyl Tablets Bowel Prep Kit; Braintree Laboratories, Inc, Braintree, Mass). During the study, bisacodyl
was administered as two 5-mg tablets, which is twice the dose strength of the currently marketed product (ie,
one 5-mg bisacodyl tablet). Two 5-mg bisacodyl tablets was the approved dose in the bowel prep kit at the time of study initiation